Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an update.
Microba Life Sciences Limited has announced its Q4 FY25 Investor Presentation and Webinar, which will be presented by CEO Dr. Luke Reid. The company invites investors and interested parties to engage with management and submit questions ahead of the webinar. This initiative aims to enhance communication with stakeholders and keep them informed about the company’s developments and strategic direction.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is a precision microbiome company focused on improving human health through world-leading technology for measuring the human gut microbiome. The company is involved in the discovery and development of novel therapeutics for major chronic diseases and provides gut microbiome testing services globally to researchers, clinicians, and consumers. Microba collaborates with leading organizations to explore new relationships between the microbiome, health, and disease to develop new health solutions.
Average Trading Volume: 293,166
Technical Sentiment Signal: Sell
Current Market Cap: A$54.08M
Find detailed analytics on MAP stock on TipRanks’ Stock Analysis page.